BioRéalités Overview

  • Founded
  • 2007
  • Status
  • Acquired/​Merged
  • Employees
  • 17
  • Latest Deal Type
  • M&A

BioRéalités General Information


Developer of monoclonal antibodies directed against factors of cancer relapses. The company helps to manage several types of cancer with a focus on colorectal cancer. The company continues to research and help identify a specific abnormal protein that causes colorectal cancer.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 2040 avenue du Père Soulas
  • 34000 Montpellier
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioRéalités Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Jul-2011 00.000 Completed Product Development
2. Early Stage VC 01-Jun-2010 00.000 00.000 Completed Product Development
1. Early Stage VC 01-Jun-2009 $3.16M $3.16M Completed Product Development
To view BioRéalités’s complete valuation and funding history, request access »

BioRéalités Executive Team (4)

Name Title Board Seat Contact Info
Jean-Francois Floch Co-Founder, Chief Executive Officer and President
Dominique Joubert Co-Founder
Frederic Hollande Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

BioRéalités Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioRéalités Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Soridec Venture Capital Minority 000 0000 000000 0
To view BioRéalités’s complete investors history, request access »